Keywords: alizyme, expects, results, phase, ii, trial, colal-pred
Alizyme expects results from Phase II trial of Colal-Pred
Article | 24 December 2001
Alizyme of the UK has completed dosing in its Phase II clinical trial ofColal-Pred (prednisolone metasulphobenzoate; formerly ATL-2502) in mild-to-moderate ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
